Successful Treatment of Drug‐Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator
Citations Over TimeTop 10% of 2001 papers
Abstract
Treatment failures for leishmaniasis with pentavalent antimonials, including meglumine antimonate, are increasingly common in many endemic areas. Imiquimod (Aldara; 3M Pharmaceuticals) is a novel immune response-activating compound, approved by the United States Food and Drug Administration, that is currently used to treat cervical warts and has been shown to activate macrophage killing of Leishmania species. Therefore, an open-label, prospective study was conducted of combined imiquimod plus meglumine antimonate therapy in 12 patients with cutaneous leishmaniasis who had previously not responded to meglumine antimonate therapy. All of the patients responded well to this combination therapy, and 90% were found to be cured at the 6-month follow-up period.
Related Papers
- → TREATMENT OF RECURRENT CUTANEOUS LEISHMANIASIS(1995)43 cited
- → Tropical medicine rounds: Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun(2010)10 cited
- → Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis(2012)10 cited
- → COMPARISON OF EFFICACY OF MILTEFOSINE VERSUS MEGLUMINE ANTIMONATE IN THE TREATMENT OF CUTANEOUS LEISHMANIASIS(2022)4 cited
- Comparison between topical treatment with thioxolone , benzoxonium chloride tincture and intralesional injection of meglumine antymoniate on cutaneous leishmaniasis(1995)